JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED – Trademark Portfolio
Entity Type: 16
JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include VERSACLOZ and FAZACLO (CLOZAPINE, USP) ORALLY DISINTEGRATING TABLETS. The owner is based in HAMILTON.
2 CHURCH STREET
CLARENDON HOUSE
HAMILTON HM11 , BM
Showing of trademarks Trademarks
Trademark Classifications
JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED have?
JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED has 7 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 abandoned, 1 cancelled.
What trademark classes does JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED file in?
JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED's most well-known trademarks?
JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED's registered trademark portfolio includes well-known marks such as VERSACLOZ and FAZACLO (CLOZAPINE, USP) ORALLY DISINTEGRATING TABLETS. These are among 2 currently registered trademarks in the portfolio.
What is JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED's trademark registration success rate?
JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.